SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff is drawing attention amid renewed concerns about its heavy debt burden, high borrowing costs and HSBCs bearish assessment of its ability to fund growth. Traders are split between viewing the decline as an overdone move that could fuel a rebound and warning that financing risks could keep pressure on the AI infrastructure provider.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

Middle East tensions and reported attacks on oil shipping and energy infrastructure have focused attention on crude supply-disruption risks, while speculation about US-Iran mediation has fueled sharp swings. Bulls point to potential supply constraints; bears argue that a deal or normalized shipping could unwind the risk premium and that the rally is overextended.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SLS is drawing attention as traders await the 80-event trigger for the Phase 3 REGAL trial of GPS; the last disclosed count was 78, and claims that the threshold has since been reached remain unconfirmed. Bulls interpret the extended trial as encouraging and speculate about a buyout or ASH update, while skeptics stress that the outcome is still uncertain and the timing unclear.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is drawing attention amid a sharp selloff in AI neocloud stocks, as investors weigh financing risks and warnings that some providers may not survive; traders are frustrated that IREN has lagged peers and debate whether the weakness is justified. Some point to the co-CEOs comments that data-center assets carry no debt and customer prepayments help fund GPU costs, while others remain concerned about sector-wide risk and continued selling.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoins rebound toward the $83,000 area has fueled talk of a breakout and possible short squeeze, with bullish traders pointing to resilient buying. Others call the move a temporary bounce and stress that Bitcoin needs to hold key levels above $82,000$83,000 to sustain momentum.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs slide to fresh lows, amid concerns about Trumps standing ahead of the midterms and Truth Socials declining appeal, dominates discussion. The community is broadly bearish, citing weak business fundamentals and continued selling, while a few traders see scope for a short-term bounce.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

SOXX is drawing attention after a prolonged semiconductor selloff and a bounce near support, with traders split between buying an oversold recovery and expecting further weakness amid AI-spending and financing concerns. Bulls are watching upcoming tech earnings and hyperscaler capex commentary for confirmation that chip demand remains strong.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

Unconfirmed reports of a potential US-Iran deal and a pullback in oil prices are central to the sharp QQQ swings, with traders attributing the rebound to reduced geopolitical risk. The community is divided between buying the move ahead of major tech earnings and warning that the deal chatter may be unreliable and the rally a bull trap, amid continued concern about AI and semiconductor weakness.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

Unconfirmed reports of a possible U.S.-Iran deal dominated discussion around SPYs sharp rally, with traders linking the reports and a drop in oil to improved risk appetite. Some chased the move as peace news; others questioned the reports credibility and called the rally a potential trap or short-lived pump.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhoods sharp selloff is driving discussion, with traders citing analyst caution, its premium valuation, broader risk-off conditions and positioning ahead of earnings as possible pressures. The community is split between calling the decline an oversold buying opportunity and expecting further weakness, while some say the move lacks a clear company-specific trigger.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?

Ono Pharmaceutical Co. (OPHLF) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

NRX Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript

NRX Pharmaceuticals (NASDAQ:NRXP) released second-quarter financial results and hosted an earnings call on Monday. Read the complete transcript below.
This content is powered by Benzinga APIs. For comprehensiveread more...

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of -100.00% and -54.13%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals Inches Toward Approval After FDA Finds No Drug Deficiencies

NRx Pharmaceuticals (NASDAQ:NRXP) reached a potentially significant regulatory milestone after announcing that the U.S. Food and Drug Administration completed its first-cycle review of the company's Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine without identifying any major deficiencies related to the drug itself. Instead, the remaining review item involves certification of the product's luer lock vial packaging, a manufacturing documentation issue rather than concerns involving safety, efficacy, labeling, chemistry, manufacturing controls, or the ketamine formulation.

ZETA SURGICAL Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics

ZETA SURGICAL Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics ZETA SURGICAL Announces Successful Treatment of First Patient with Zeta TMS Navigation System at HOPE Therapeutics PR Newswire SARASOTA, Fla, and BOSTON, June 23, 2026 SARASOTA, Fla...

NRx Pharmaceuticals (NRXP) Stock Fell 19% After Hours On Tuesday: Here's Why

NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise capital for growth and operations.read more...

NRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue Estimates

NRx Pharmaceuticals (NRXP) delivered earnings and revenue surprises of +20.00% and -91.28%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

NRx Pharmaceuticals Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

NRx Pharma (NRXP) set to release Q1 earnings on May 18. Analysts expect $19.43 million in revenue, with a loss of 11 cents per share. FDA clearance received for clinical trial.read more...

D. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)

D. Boral Capital restated a 'buy' rating and issued a $34.00 price objective on shares of NRx Pharmaceuticals in a research note on Tuesday...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short Interest

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP - Get Free Report) was the recipient of a significant growth in short interest during the month of April. As of April 15th, there was short interest totaling...

NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company was founded by Jonathan C. Javitt on September 18, 2017 and is headquartered in Wilmington, DE.

NRX Pharmaceuticals Inc

Why Did NRXP Stock Surge 21% Pre-Market Today?

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The move is a major step toward FDA approval of NRX-100, its investigational drug.</li><li>Currently, no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.</li><li>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting.</li></ul>NRx Pharmaceuticals, Inc. (NRXP) on Wednesday announced that it has licensed Real World Evidence (RWE) from more than 70,000 U.S. patients who received either intravenous ketamine or nasal S-ketamine as part of their treatment.The move is a major step toward FDA approval of its investigational drug, NRX-100 (preservative-free ketamine), aimed at treating suicidal ideation in patients with depression and suicidal tendencies.&nbsp;<h2 class="st-heading-2">Collaboration With Osmind</h2>The RWE data comes from Osmind, a neuropsychiatry technology platform used across U.S. clinics, providing detailed, regulatory-grade patient records. This joint effort allows NRx to submit a comprehensive dataset to the FDA in support of Accelerated Approval for NRX-100 under its Fast Track Designation.&nbsp;The approach could mark a breakthrough, as currently no FDA-approved medications exist specifically to treat suicidal thoughts, with electroshock therapy remaining the only sanctioned option.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/NRXP">NRx Pharmaceuticals' stock&nbsp;</a>traded over 21% higher in Wednesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ territory from ‘bearish’ the previous day. Message volume shifted to ‘high’ from ‘normal’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">Preliminary Findings And Expectations</h2>Earlier, Osmind presented data from a 20,000-patient subset at the 2024 American Society of Clinical Psychopharmacology meeting. Results suggested rapid improvement in depression and suicidal ideation with intravenous ketamine.&nbsp;NRx anticipates that analysis of the full 70,000-patient dataset will provide even stronger evidence to support the FDA submission.<blockquote>“An American commits suicide every 11 minutes and ketamine has become widely used off label as a drug that has been seen to reduce suicidal ideation in clinical trials.”-Jonathan Javitt, Chairman and CEO, NRx Pharmaceuticals</blockquote>NRXP stock has declined by over 58% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-nrxp-stock-surge-pre-market-today/cmULXc2R4eL">Why Did NRXP Stock Surge 21% Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a hand holding a medical syringe seen displayed in front of the NRx Pharmaceuticals logo.

The company is using a large US real-world evidence dataset to support its accelerated FDA approval for its ketamine-based drug.

iShares Biotechnology ETF

iShares U.S. Pharmaceuticals ETF

VanEck Pharmaceutical ETF

SPDR S&P Biotech ETF

Double beat (rev + EPS)

Revenue beat, EPS miss

EPS beat, revenue miss

Double miss

SpaceX ($SPCX) reports earnings after the close today. What do you expect?

Stocktwits

SpaceX

) reports earnings after the close today. What do you expect?

Current Price	$2.73
Prev Close	$2.63
Open	$2.61
Dividend Yield	0.00%
50-Day Moving Average	$3.21
Beta	1.30
Avg. Volume	659,123.07
PE Ratio	-3.57

52-Week High	$5.06
52-Week Low	$1.62
Market Capitalization	$113.87M
EPS (Annual)	-$1.34
Price to Book	-667.51
Revenue Per Employee	$42,241.38

Feed

News

Sentiment

Earnings

Fundamentals

Info

NRXP Fundamentals